Neuroendocrine tumours of the lung are a rare but important group of cancers that require careful management and tailored treatment approaches. Understanding the available treatment options—from standard surgical procedures to innovative therapies being tested in clinical trials—can help patients and their families navigate the complex journey ahead.

Understanding Treatment Goals for Lung Neuroendocrine Tumours

When someone receives a diagnosis of a neuroendocrine tumour of the lung, the path forward depends on many factors. These tumours originate from special cells in the lung that help regulate breathing and other bodily functions. Treatment isn’t one-size-fits-all—it varies significantly based on the specific type of tumour, how quickly it’s growing, whether it has spread to other parts of the body, and the overall health of the patient.^[1][3]

The main goals of treatment include controlling tumour growth, managing symptoms, preventing the cancer from spreading, and improving quality of life. For some patients with slow-growing tumours detected early, treatment may aim for a cure. For others with more advanced disease, the focus shifts to slowing progression and maintaining comfort. Medical professionals follow established treatment guidelines approved by international medical societies, while researchers continue to explore new therapies through clinical trials that may offer additional hope.^[8][9]

The treatment landscape includes both standard approaches with proven track records and experimental therapies being studied for their potential benefits. Each patient’s treatment plan is developed by a team of specialists who consider the unique characteristics of their disease and personal circumstances.^[8]

Standard Treatment Approaches

Surgery as Primary Treatment

Surgery remains the cornerstone of treatment for lung neuroendocrine tumours, particularly for the slower-growing types called typical carcinoid and atypical carcinoid. When the tumour is caught early and hasn’t spread beyond the lung, surgical removal may be the only treatment needed. The type of operation depends on where the tumour is located and how large it has grown.^[8][12]

A lobectomy, which involves removing one section of the lung, is the most common procedure. The lung is divided into sections called lobes—three on the right side and two on the left. Surgeons remove the affected lobe along with nearby lymph nodes to check whether cancer has spread. Some patients may need a bilobectomy, removing two lobes, or in more extensive cases, a pneumonectomy, which means removing the entire lung. For smaller tumours, a wedge resection or segmentectomy removes just the affected portion, preserving more lung tissue.^[8]

For typical carcinoid tumours diagnosed at an early stage, surgery alone often provides excellent outcomes. These slow-growing tumours have a five-year survival rate of around 85% to 95% when caught early. Atypical carcinoids, which grow slightly faster, have survival rates ranging from 40% to 70%, with better outcomes when the disease is localized.^[1][12]

Chemotherapy for More Aggressive Types

For the more aggressive forms of lung neuroendocrine tumours—particularly small cell carcinoma and large cell neuroendocrine carcinoma—chemotherapy plays a central role in treatment. These fast-growing cancers often respond well initially to chemotherapy drugs, which work by targeting rapidly dividing cells throughout the body.^[8][12]

Small cell carcinoma, the most aggressive type, tends to grow rapidly and is frequently diagnosed at an advanced stage when treatment options are more limited. The five-year survival rate for small cell carcinoma typically ranges from 20% to 30%. However, chemotherapy can help control the disease, shrink tumours, and relieve symptoms. Treatment usually involves combinations of different chemotherapy drugs given in cycles, allowing the body time to recover between treatments.^[1][12]

Side effects from chemotherapy vary depending on the specific drugs used but commonly include fatigue, nausea, hair loss, increased infection risk, and changes in appetite. These effects are generally temporary and improve after treatment ends. Medical teams carefully monitor patients throughout chemotherapy and can adjust doses or provide supportive medications to manage side effects.^[12]

Radiation Therapy

Radiation therapy uses high-energy beams to destroy cancer cells. It may be used in several situations for lung neuroendocrine tumours. Sometimes radiation is given after surgery to destroy any remaining cancer cells, particularly if the tumour couldn’t be completely removed or if cancer was found in lymph nodes. For patients who cannot undergo surgery due to other health conditions, radiation may serve as the primary treatment.^[8][12]

Radiation can also provide relief when cancer has spread to other parts of the body, particularly to the brain or bones, where it can cause pain or other symptoms. The treatment is typically given five days a week over several weeks, with each session lasting only a few minutes. Modern radiation techniques aim to target cancer cells precisely while minimizing damage to surrounding healthy tissue.^[8]

Somatostatin Analogues

Somatostatin analogues are medications that can help control symptoms and slow tumour growth in some lung neuroendocrine tumours. These drugs mimic a natural hormone in the body called somatostatin, which can reduce the production of other hormones that fuel tumour growth. They’re particularly useful for patients who develop carcinoid syndrome, a collection of symptoms caused when tumours release excessive hormones into the bloodstream.^[9]

Symptoms of carcinoid syndrome include skin flushing (reddening and warmth of the face and upper body), diarrhea, wheezing, and rapid heartbeat. While carcinoid syndrome is less common in lung neuroendocrine tumours compared to those starting in the digestive system, it can occur, especially if the cancer has spread to the liver. Somatostatin analogues are given as injections, typically once a month, and can significantly improve quality of life by controlling these troublesome symptoms.^[3][9]

Immunotherapy

Immunotherapy is a newer class of treatment that helps the body’s own immune system recognize and attack cancer cells. For lung neuroendocrine carcinomas, particularly large cell neuroendocrine carcinoma, immunotherapy drugs may be used alongside chemotherapy. These medications work differently than traditional chemotherapy—instead of directly killing cancer cells, they remove the “brakes” that prevent the immune system from attacking the tumour.^[8]

While immunotherapy has shown promise, it doesn’t work for everyone. Doctors may test tumour samples to determine whether a patient is likely to benefit from this approach. Side effects from immunotherapy differ from those of chemotherapy and can include fatigue, skin rashes, and inflammation of various organs. These effects occur because the activated immune system sometimes attacks healthy tissues along with cancer cells.^[8]

Targeted Cancer Drugs

Targeted cancer drugs are designed to interfere with specific molecules involved in tumour growth and survival. Unlike chemotherapy, which affects all rapidly dividing cells, targeted drugs focus on particular abnormalities present in cancer cells. For some lung neuroendocrine tumours, doctors may recommend testing the tumour for specific genetic changes that could be targeted with these drugs.^[8]

The use of targeted therapy depends on finding specific alterations in the cancer cells that can be addressed with available medications. This personalized approach means treatment is tailored to the unique characteristics of each patient’s tumour, potentially offering better results with fewer side effects than traditional chemotherapy.^[9]

Treatment Duration and Monitoring

The duration of treatment varies widely depending on the type and stage of lung neuroendocrine tumour. Surgery is a one-time event followed by a recovery period and regular monitoring. Chemotherapy is typically given in cycles spanning several months. Somatostatin analogues may be continued long-term to control symptoms and slow disease progression. Some lung neuroendocrine tumours grow so slowly that doctors may recommend careful monitoring without immediate treatment, an approach called “watchful waiting.”^[8][12]

Throughout treatment, patients undergo regular imaging scans, blood tests, and physical examinations to assess how well the therapy is working and to catch any changes early. This ongoing monitoring continues even after treatment is completed, as lung neuroendocrine tumours can sometimes return months or years later.^[8]

Treatment in Clinical Trials

What Are Clinical Trials?

Clinical trials are carefully designed research studies that test new treatments or new combinations of existing treatments. They represent the pathway through which promising experimental therapies become standard care. For patients with lung neuroendocrine tumours, clinical trials may offer access to innovative approaches not yet widely available. Participation in a clinical trial is always voluntary and doesn’t prevent patients from receiving standard treatment if the experimental therapy doesn’t work.^[9]

Clinical trials progress through phases, each with specific goals. Phase I trials primarily assess safety, determining the appropriate dose and identifying side effects in a small group of patients. Phase II trials expand to more patients and focus on whether the treatment shows signs of effectiveness against the cancer. Phase III trials involve large groups of patients and compare the new treatment directly against current standard therapy to determine if it offers improvements in outcomes or quality of life.^[9]

Peptide Receptor Radionuclide Therapy

One promising treatment being studied for lung neuroendocrine tumours is peptide receptor radionuclide therapy (PRRT). This innovative approach combines a targeting molecule with a radioactive substance. The targeting molecule seeks out specific receptors on neuroendocrine tumour cells, delivering radiation directly to the cancer while sparing surrounding healthy tissue.^[9]

PRRT works particularly well for tumours that have high levels of somatostatin receptors on their surface—something that can be determined through special imaging scans. The treatment is given through an intravenous infusion, typically in multiple cycles spaced several weeks apart. Clinical trials have shown that PRRT can help control disease progression and improve symptoms in patients with advanced neuroendocrine tumours. Side effects may include temporary changes in blood counts, kidney function, and occasionally bone marrow effects, which are carefully monitored throughout treatment.^[9]

New Chemotherapy Combinations and Approaches

Researchers continue to explore different combinations of chemotherapy drugs and novel ways to deliver them specifically to lung neuroendocrine tumours. Some clinical trials investigate whether adding newer chemotherapy agents to established regimens can improve outcomes for patients with aggressive forms of the disease. Others examine whether lower doses given more frequently might be as effective as standard schedules while causing fewer side effects.^[9]

For lung carcinoids—the slower-growing types—chemotherapy hasn’t traditionally been a first-line treatment. However, ongoing studies are evaluating whether specific chemotherapy drugs might benefit patients whose disease has spread or returned after surgery. These trials carefully track not just tumour response but also quality of life, helping doctors understand the full impact of treatment.^[9]

Advanced Immunotherapy Studies

While immunotherapy has become established for some aggressive lung neuroendocrine carcinomas, research continues into how to make these treatments work for more patients. Clinical trials are testing combinations of different immunotherapy drugs, pairing immunotherapy with chemotherapy in various sequences, and investigating biomarkers that might predict which patients will benefit most.^[9]

Some studies focus specifically on understanding why certain neuroendocrine tumours respond to immunotherapy while others don’t. This research examines the tumour microenvironment—the ecosystem of cells, blood vessels, and immune cells surrounding the cancer—to identify ways to make resistant tumours more susceptible to immune attack. Preliminary results from these studies have helped refine patient selection and treatment strategies.^[9]

Targeted Therapy Development

Scientists are identifying molecular pathways that drive neuroendocrine tumour growth and developing drugs to block these pathways. Several targeted drugs are being tested in clinical trials for lung neuroendocrine tumours, focusing on proteins and enzymes that cancer cells need to survive and multiply.^[9]

One area of investigation involves drugs that block blood vessel formation around tumours. Cancer cells need nutrients delivered by blood vessels to grow, and cutting off this supply can slow or stop tumour progression. Another research direction targets the internal signaling systems that tell cancer cells to divide. By interrupting these signals, targeted drugs may stop tumour growth with fewer side effects than traditional chemotherapy.^[9]

These trials often require genetic testing of tumour samples to identify patients whose cancers have the specific alterations the drug is designed to target. This personalized approach represents the future of cancer treatment, matching each patient with therapies most likely to help them based on their tumour’s unique molecular profile.^[9]

Participation and Availability

Clinical trials for lung neuroendocrine tumours are conducted at specialized medical centers around the world, including facilities in the United States, Europe, and Australia. Eligibility depends on many factors, including the type and stage of disease, previous treatments received, overall health status, and sometimes specific characteristics of the tumour identified through testing.^[1]

Patients interested in clinical trials should discuss options with their medical team. Oncologists can help determine which trials might be appropriate and explain the potential benefits and risks. Many trials cover the cost of the experimental treatment and associated monitoring, though patients should clarify financial aspects before enrolling. Participation in clinical trials not only may provide access to cutting-edge therapies but also contributes to advancing medical knowledge that will help future patients.^[9]

Most Common Treatment Methods

• Surgery
  • Lobectomy to remove one section of the lung affected by the tumour
  • Bilobectomy to remove two lobes of the lung
  • Pneumonectomy to remove the entire lung in extensive cases
  • Wedge resection or segmentectomy for smaller tumours, preserving more lung tissue
  • Lymphadenectomy to remove nearby lymph nodes for testing
• Chemotherapy
  • Standard treatment for aggressive types like small cell carcinoma and large cell neuroendocrine carcinoma
  • Given in cycles with recovery periods between treatments
  • Combinations of different drugs to target rapidly dividing cancer cells
  • Used when surgery is not possible or after surgery to destroy remaining cancer cells
• Radiation Therapy
  • High-energy beams to destroy cancer cells
  • Given after surgery to eliminate remaining cancer cells
  • Used as primary treatment for patients who cannot undergo surgery
  • Provides symptom relief when cancer has spread to brain or bones
• Somatostatin Analogues
  • Long-acting injections given typically once monthly
  • Controls symptoms of carcinoid syndrome including flushing and diarrhea
  • Can slow tumour growth in certain neuroendocrine tumours
  • Mimics natural hormone that reduces production of tumour-fueling hormones
• Immunotherapy
  • Helps the immune system recognize and attack cancer cells
  • Used particularly for large cell neuroendocrine carcinoma
  • May be combined with chemotherapy
  • Removes barriers preventing immune system from attacking tumours
• Targeted Cancer Drugs
  • Interferes with specific molecules involved in tumour growth
  • Requires genetic testing to identify targetable alterations
  • Personalized approach based on tumour’s unique characteristics
  • Potentially offers better results with fewer side effects than traditional chemotherapy
• Peptide Receptor Radionuclide Therapy (PRRT)
  • Experimental treatment combining targeting molecule with radioactive substance
  • Delivers radiation directly to tumour cells with somatostatin receptors
  • Given through intravenous infusion in multiple cycles
  • Studied in clinical trials for advanced neuroendocrine tumours